'Banned pregnancy drug impacts fetal immune system'

Researchers document lifelong health complications facing daughters of women given a synthetic estrogen prescribed to women in the 1940s, 1950s, 1960s.

By VIRGINIA POLYTECHNIC INSTITUTE, STATE UNIVER
October 12, 2011 14:15
1 minute read.
Illustrative photo

pregnant woman 311. (photo credit: Ariel Jerozolimski [illustrative])

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

A synthetic estrogen — diethylstilbestrol (DES), prescribed to women in the 1940s, 1950s, and 1960s to prevent miscarriages, had serious, untoward effects in daughters of these women, including the development of a rare type of cancer of the uterus. There has been renewed interest in light of a recent report in the New England Journal of Medicine documenting lifelong health complications facing daughters of women given DES.

Reproductive tissues are not the only targets of DES. The immune system is also known to be a target for estrogens. Dr. S. Ansar Ahmed, professor of immunology at Virginia Tech, led a National Institutes of Health study in the 1990s on how exposure to DES in utero affects the immune system later in life using a mouse model.

Be the first to know - Join our Facebook page.


“We decided to look at how giving DES to mothers changes the immune system after birth,” Ahmed said. “Exposure to hormones such as DES can create a different environment for the fetal immune system. This is a very sensitive time in the ‘education’ of the immune system. Exposure of the fetus to DES during this sensitive time can interfere with this ‘education’ of the immune system.”

According to Ahmed, many disorders resulting from prenatal exposure to DES become evident after puberty and maturity. This suggested to Ahmed and his colleagues that individuals exposed to DES prenatally might have a “deviant or more sensitive” response to their own sex hormones at maturity.

The New England Journal of Medicine report found that women whose mothers took DES have significantly higher rates of a number of reproductive problems, including infertility, miscarriage, and premature births. There are more than two million women in the United States who were exposed to DES in utero.

The US Food and Drug Administration banned pregnant women from using the drug after a 1971 study found that it caused a rare vaginal tumor in girls and women exposed to it.

This article was first published at www.newswise.com

Related Content

Lab
August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice

By JUDY SIEGEL-ITZKOVICH